Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data

BACKGROUND: Although sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) improve not only glycemic control but also liver inflammation and fatty changes in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM), its sustainability and effect on liver fibrosis ha...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ther Adv Endocrinol Metab
Päätekijät: Arai, Taeang, Atsukawa, Masanori, Tsubota, Akihito, Mikami, Shigeru, Ono, Hiroki, Kawano, Tadamichi, Yoshida, Yuji, Tanabe, Tomohide, Okubo, Tomomi, Hayama, Korenobu, Nakagawa-Iwashita, Ai, Itokawa, Norio, Kondo, Chisa, Kaneko, Keiko, Emoto, Naoya, Nagao, Mototsugu, Inagaki, Kyoko, Fukuda, Izumi, Sugihara, Hitoshi, Iwakiri, Katsuhiko
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: SAGE Publications 2021
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7989116/
https://ncbi.nlm.nih.gov/pubmed/33815743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20420188211000243
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia